Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

被引：1
|
作者：
Atkins, CD
机构：
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1998年 / 90卷 / 06期
关键词：
D O I：
10.1093/jnci/90.6.468
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：468 / 468
页数：1
相关论文
共 50 条
  • [41] What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?
    Ando, Kenju
    Shimomura, Akihiko
    Yoshimura, Kenichi
    Kawamura, Yukino
    Shimizu, Chikako
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (17) : 1946 - +
  • [42] MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer
    Choschzick, Matthias
    Heilenkoetter, Uwe
    Lebeau, Annette
    Jaenicke, Fritz
    Terracciano, Luigi
    Bokemeyer, Carsten
    Sauter, Guido
    Simon, Ronald
    CANCER BIOMARKERS, 2010, 8 (02) : 53 - 60
  • [43] NODE-NEGATIVE BREAST-CANCER - TAMOXIFEN AND CHEMOSUPPRESSION
    JORDAN, VC
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (12) : 1068 - 1069
  • [44] DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer
    Debien, Veronique
    Adam, Virginie
    Coart, Elisabeth
    Agostinetto, Elisa
    Goulioti, Theodora
    Molinelli, Chiara
    Arahmani, Amal
    Zoppoli, Gabriele
    Piccart, Martine
    FUTURE ONCOLOGY, 2023, 19 (24) : 1655 - 1667
  • [45] Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score
    Meisel, Jane
    Zhang, Chao
    Neely, Cameron
    Menduza, Pia
    You, Shuo
    Han, Tatiana
    Liu, Yuan
    Sahin, Aysegul A.
    O'Regan, Ruth
    Li, Xiaoxian
    CLINICAL BREAST CANCER, 2018, 18 (05) : 347 - 352
  • [46] Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer
    Jacqueline Tsai
    Danielle Bertoni
    Tina Hernandez-Boussard
    Melinda L. Telli
    Irene L. Wapnir
    Annals of Surgical Oncology, 2016, 23 : 3310 - 3316
  • [47] Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review)
    Viedma-Rodriguez, Rubi
    Baiza-Gutman, Luis
    Salamanca-Gomez, Fabio
    Diaz-Zaragoza, Mariana
    Martinez-Hernandez, Guadalupe
    Ruiz Esparza-Garrido, Ruth
    Angel Velazquez-Flores, Miguel
    Arenas-Aranda, Diego
    ONCOLOGY REPORTS, 2014, 32 (01) : 3 - 15
  • [48] Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer
    Tsai, Jacqueline
    Bertoni, Danielle
    Hernandez-Boussard, Tina
    Telli, Melinda L.
    Wapnir, Irene L.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (10) : 3310 - 3316
  • [49] Steroid Receptor RNA Activator Protein (SRAP): A Potential New Prognostic Marker for Estrogen Receptor-Positive/Node-Negative/Younger Breast Cancer Patients
    Yan, Y.
    Skliris, G. P.
    Penner, C. C.
    Chooniedass-Kothari, S.
    Cooper, C.
    Nugent, Z.
    Fristenski, A.
    Hamedani, M. K.
    Blanchard, A.
    Myal, Y.
    Murphy, L. C.
    Leygue, E.
    CANCER RESEARCH, 2009, 69 (24) : 597S - 597S
  • [50] Survival Benefit of Tamoxifen in Estrogen Receptor-Negative and Progesterone Receptor-Positive Low Grade Breast Cancer Patients
    Yang, Li-Heng
    Tseng, Hsin-Shun
    Lin, Che
    Chen, Li-Sheng
    Chen, Shou-Tung
    Kuo, Shou-Jen
    Chen, Dar-Ren
    JOURNAL OF BREAST CANCER, 2012, 15 (03) : 288 - 295
12345